-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Raises Price Target to $35

Benzinga·12/17/2025 20:12:54
語音播報
Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $24 to $35.